Latest News
Eyevance Pharmaceuticals Acquires Freshkote Lubricant Eye Drop Line from Focus Laboratories
Thursday 13 September 2018

13 September 2018 - US-based pharmaceutical company Eyevance Pharmaceuticals, LLC has acquired the Freshkote lubricant eye drops line of products from Focus Laboratories, Inc, the company said.

Under the terms of the agreement, Eyevance acquired Freshkote and all its formulations, including the preservative-free multi-dose bottle and single-unit vials to market and commercialize worldwide.

New Freshkote PF is designed to support the integrity of all three layers of the eye's tear film, offering dry eye patient's relief from their symptoms.

Freshkote PF combats evaporation on the ocular surface with a patented polymer blend formulated to mimic the lipid layer of the tear film.

Notably, due to its non-irritating profile, Freshkote PF is safe for contact lens wearers and can be used on an as-needed basis.

A non-prescription product, new Freshkote PF is available in 10-mL multi-dose bottles or boxes of 30 single-unit vials. Freshkote PF can be professionally recommended to patients and sold behind the pharmacy counter.

Eyevance's acquisition of the Freshkote family of products follows the announcement of an exclusive licensing agreement with Nicox Ophthalmics, Inc. for prescription-only Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis.

Eyevance plans to launch Zerviate in early 2019.

Eyevance Pharmaceuticals is a Fort Worth-based company committed to developing and commercialising ophthalmic products.

Focus Laboratories is a specialty eye care company dedicated to addressing the needs of healthcare providers and their patients through the discovery and development of innovative medicines and devices that support eye health and improve the quality of life.

VelocityHealth Securities is acting as exclusive financial advisor and Burke, Warren, McKay and Serritella, P.C. and Greenblum and Bernstein, plc are acting as legal advisors to Eyevance.
Details
Date Published: 13/09/2018
Target: Focus Laboratories
Country: USA
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing:
Status: Closed
Vendor:
Buyer: Eyevance Pharmaceuticals
Buyer Advisor: VelocityHealth Securities , Burke, Warren, McKay and Serritella , Greenblum and Bernstein
Comment:
Terms of the deal were not disclosed

Options